Olaratumab

Grey

Brand Name(s):Lartruvo

Indication:Soft tissue sarcoma

Rationale:3

Considered:Jan-17

Review Date:Jul-24

Comments:
Drug Safety Update
Lartruvo: withdrawal of the EU marketing authorisation due to lack of efficacy
June 2019